Synageva BioPharma to Present at the Jefferies 2012
.....Synageva BioPharma to Present at the Jefferies 2012 Global Health Care Conference
LEXINGTON, Mass Synageva BioPharma Corp. (“Synageva”) (GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, will present at the Jefferies 2012 Global Health Care Conference being held in New York City.
Carsten Boess, Chief Financial Officer of Synageva, will present on Monday, June 4, 2012, at 11:30 a.m. EDT. The presentation will be webcast live and may be accessed from the “Webcasts & Presentations” section of the Investor Relations tab on the home page of Synageva’s website at www.synageva.com.
About Synageva’s Lead Program
SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme. SBC-102 is currently being evaluated in global clinical trials and has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency. Additionally, SBC-102 received fast track designation by the FDA.
About LAL Deficiency
Lysosomal Acid Lipase Deficiency is a rare, autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease in LAL enzyme activity. Late onset LAL Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In these patients, the buildup of fatty material in the liver, spleen and blood vessel walls leads to complications resulting in significant morbidity and mortality. Early onset LAL Deficiency, sometimes called Wolman Disease, affects infants in the first year of life and is characterized by growth failure, malabsorption, steatorrhea and hepatomegaly and is rapidly fatal, usually within the first year of life.